Project Optimus PrimePresentation to the Special Committee November 21, 2022

Optimus Prime Historical and Forecasted Financial Overview (Management Case) Source: Company filings, historical financials and management forecasts provided by the Company on 11/01/2022 (approved for our use by the Special Committee) Note: (1) Excludes acquisitions ($ in millions, all years reflect CY year-end 12/31) (1)

Unaffected Ratings History Price Target by Broker(1) Equity Analyst View of Optimus Prime Stock Select Broker Commentary Source: Wall Street research, Capital IQ as of 11/18/2022 Note: (1) HC Wainwright placed Optimus Prime stock under review due to proposed buyout and did not offer a price target or rating in most recent report dated 11/10/2022 Roth Capital Partners 11/10/2022 Lake Street Capital Markets 11/10/2022 BMO Capital Markets 11/10/2022 Buy Hold “[Company] offers among the broadest product offerings in the food waste category and believe double-digit growth from its next-generation products seen since 2021 can continue to deliver alpha from current levels.” – Lake Street Capital Markets (11/10/2022) “… the increase in revenue was approximately 3.1% YoY. We believe revenue growth was supported by results from diversification efforts.” – HC Wainwright (11/10/2022) “[Company] continues to execute on its diversification strategy posting the seventh consecutive quarter of growth.” – Roth Capital Partners (11/10/2022) “We slightly lower estimates following a disappointing Q3 update largely owing to FX … [Company] earnings remain somewhat flattish with a slight trajectory upward.” – BMO Capital Markets (11/10/2022)

Last 12 Months Share Price and Trading Volume Since De-spac (08/03/2015) Optimus Prime Stock Price Performance Source: Capital IQ as of 11/18/2022 Notes: High Value Specialties includes Croda, Chr Hansen, Balchem and Novozymes; Large AgChem includes Nutrien, Mosaic, FMC Corp, CF Industries, Dow, Bayer, Corteva, BASF, Nufarm and UPL Limited; AgChem / AgTech includes FMC Corp, Scotts Miracle-Gro, Bioceres and American Vanguard; Food Safety / Security includes Ecolab, Sotera, Diversey and Neogen Offer Price: $3.00 Offer Price: $3.00 06/15/20: Announces $150M convertible preferred equity investment from Paine Schwartz Partners 10/27/2022: Announces the Special Committee of Optimus Prime agreed with Paine Schwartz Partners to pursue a transaction in which Paine Schwartz Partners would acquire all outstanding common stock for $3.00 per share 10/27/2022: Trading volume peaked at 39M+ shares (not shown to scale); next highest volume during LTM occurred on 10/28/2022 at ~2.1M shares Unaffected (10/26/2022) Optimus Prime VWAPs 30-Day $1.58 60-Day $1.60 90-Day $1.68

Unaffected EV and Valuation EV / NTM EBITDA Over Time (Since January 2019)(6)(7) Optimus Prime Public Market Trading Multiple Over Time Share Price (10/26/2022)(1) $1.57 (x) Fully Diluted Shares(2) 58.460 Equity Value $91.8 (-) Cash(3) (35.6) (+) Debt(4) 261.3 (+) Preferred at Liquidation Preference(5) 253.7 (+) Non-Controlling Interest(3) 6.9 Enterprise Value $578.1 Management Case Multiples CY2022E CY2023E EV / Revenue 3.5x 3.2x EV / EBITDA 9.6x 9.1x Consensus Multiples CY2022E CY2023E EV / Revenue 3.5x 3.2x EV / EBITDA 9.9x 9.1x Source: Company filings, Historical financials and management forecasts provided by the Company on 11/01/2022 (approved for our use by the Special Committee), FactSet and Capital IQ as of 11/18/2022 Notes: (1) Unaffected stock price prior to the announcement of Paine Schwartz Partners’ take-private of Optimus Prime (2) Calculated as basic shares outstanding plus the effects of dilutive securities provided by the Company on 11/18/2022 (3) As of Q3 2022 (4) Includes principal value of Term Loan B ($260.438M) and Optimus Prime Fruit Protection Loan ($0.897M) per Q3 2022 10-Q (5) Reflects change of control for Paine Schwartz Partners' convertible preferred equity at 2.0x MOIC assuming redemption date of 01/31/2023; liquidation preference assumes 50% cash / 50% PIK split for future preferred stock dividends (vs. option to elect 62.5% cash / 37.5% PIK split) based on management assumptions (6) Earliest publication of 3rd party EV/NTM EBITDA data after De-SPAC on 08/03/2015 (7) Convertible preferred equity not reflected in EV / NTM EBITDA over time for Optimus Prime 06/15/2020: Announces $150M convertible preferred equity investment from Paine Schwartz Partners 10/27/2022: Announces the Special Committee of Optimus Prime agreed with Paine Schwartz Partners to pursue a transaction in which Paine Schwartz Partners would acquire all outstanding common stock for $3.00 per share Offer EV and Valuation Offer Price $3.00 (x) Fully Diluted Shares(2) 58.460 Offer Value $175.4 (-) Cash(3) (35.6) (+) Debt(4) 261.3 (+) Preferred at Liquidation Preference(5) 253.7 (+) Non-Controlling Interest(3) 6.9 Enterprise Value $661.7 Management Case Multiples CY2022E CY2023E EV / Revenue 4.0x 3.7x EV / EBITDA 11.0x 10.4x Consensus Multiples CY2022E CY2023E EV / Revenue 4.0x 3.7x EV / EBITDA 11.3x 10.4x ($ in millions, except share price)

Valuation Summary Unaffected (10/26) Price: $1.57 Source: Company filings, historical financials and management forecasts provided by the Company on 11/01/2022 (approved for our use by the Special Committee) Notes: Unaffected share price as of 10/26/2022 Enterprise value-based valuation methodologies reflect change of control for Paine Schwartz Partners' convertible preferred equity at 2.0x MOIC assuming redemption date of 01/31/2023; liquidation preference assumes 50% cash / 50% PIK split for future preferred stock dividends (vs. option to elect 62.5% cash / 37.5% PIK split) based on management assumptions (1) Broker price targets represent 12-month targets; prices discounted 12 months from date of publication to 10/26/2022; reflects latest unaffected price targets; assumes cost of equity of 19.0% (2) Based on unaffected current median of AgChem / AgTech and unaffected Optimus Prime 2023E trading multiple (3) Based on +/- 1.0x vs. median of precedent transactions (4) Core Products WACC range derived using cost of equity implied by CAPM at optimal capital structure (~13.0% WACC) and cost of equity implied by the yield on Paine Schwartz Partners' preferred equity investment in Optimus Prime assuming redemption on 07/27/2023 at current capital structure (~15.5% WACC) (5) New Products WACC assumed to be 200 bps greater than Core Products WACC to reflect greater execution risk; assumes full achievability of New Products (1) Offer Price: $3.00 (2) (4) (5) (4) (5) (3)

EV / CY2023E EBITDA EV / CY2022E EBITDA Current Public Market Valuations of Selected Peers Source: Company filings, historical financials and management forecasts provided by the Company on 11/01/2022 (approved for our use by the Special Committee), FactSet and Capital IQ as of 11/18/2022 Notes: (1) Reflects change of control for Paine Schwartz Partners' convertible preferred equity at 2.0x MOIC assuming redemption date of 01/31/2023; liquidation preference assumes 50% cash / 50% PIK split for future preferred stock dividends (vs. option to elect 62.5% cash / 37.5% PIK split) based on management assumptions Optimus Prime (Offer)(1) Optimus Prime (Unaffected) (1) Optimus Prime (Offer) (1) Optimus Prime (Unaffected) (1) AgChem / AgTech High Value Specialties Food Safety / Security

Date 12/21/2021 12/14/2021 6/28/2021 3/24/2021 10/19/2020 10/12/2020 7/17/2020 9/30/2019 7/20/2018 4/30/2015 9/11/2014 Acquirer Target Enterprise Value ($M) $198 $5,300 $170 $402 $165 $1,500 $1,142 $1,188 $4,200 $879 $2,773 EV / EBITDA for Select Precedent Transactions Select Precedent Transactions Source: Company filings, Moody’s, press releases (Food Safety Business) (South American Plan Nutrition Business) Mean: 11.4x Median: 10.2x

Discounted Cash Flow Analysis – Management Case New Products Unlevered Free Cash Flows Core Products Unlevered Free Cash Flows Combined Terminal Value Build and Valuation Sources: Company filings, historical financials and management forecasts provided by the Company on 11/10/2022 (approved for our use by the Special Committee), FactSet as of 11/18/2022 Notes: Assumes valuation date of 11/18/2022; assumes tax rate of 25.0%; fiscal year ends Dec. 31; WACCs of 14.25% and 16.25% utilized for Core Products and New Products respectively; perpetuity growth rates of 1.0% and 3.0% utilized for Core Products and New Products, respectively; D&A, SBC, and change in NWC allocated based on in-year sales contribution; CapEx allocated based on forward year sales contribution (excl. 2032E); assumes full achievability of New Products (1) 2022E-2026E amortization sourced from Q3 2022 10-Q estimated annual amortization schedule; 2027E-2032E amortization assumed to decrease by (0.5%) each year (2) Change in NWC as a % of change in revenue held constant from 2027E (3) As of Q3 2022 (4) Includes principal value of Term Loan B ($260.438M) and Optimus Prime Fruit Protection Loan ($0.897M) per Q3 2022 10-Q (5) Reflects change of control for Paine Schwartz Partners' convertible preferred equity at 2.0x MOIC assuming redemption date of 01/31/2023; liquidation preference assumes 50% cash / 50% PIK split for future preferred stock dividends (vs. option to elect 62.5% cash / 37.5% PIK split) based on management assumptions (6) Calculated as basic shares outstanding plus the effects of dilutive securities provided by the Company on 11/18/2022 (5) (2) (1) (1) (2) (1) (1) (4) (3) (3) (6) ($ in millions, except share price)

Discounted Cash Flow Sensitivities – Management Case Enterprise Value Sensitivity – Combined(1)(2) Implied Share Price Sensitivity(1)(2) Enterprise Value Sensitivity – Core Products(1) Enterprise Value Sensitivity – New Products(2) Sources: Historical financials and management forecasts provided by the Company on 11/10/2022 (approved for our use by the Special Committee) Notes: Assumes valuation date of 11/18/2022; assumes tax rate of 25.0%; fiscal year ends Dec. 31; assumes full achievability of New Products (1) Core Products WACC range derived using cost of equity implied by CAPM at optimal capital structure (~13.0% WACC) and cost of equity implied by the yield on Paine Schwartz Partners' preferred equity investment in Optimus Prime assuming redemption on 07/27/2023 at current capital structure (~15.5% WACC) (2) New Products WACC assumed to be 200 bps greater than Core Products WACC to reflect greater execution risk ($ in millions, except share price)

Precedent Premia Analysis Source: FactSet as of 11/18/2022 Notes: Unaffected premiums shown for acquisitions since 11/18/2020 with a transaction value between $100M – $3B and targets in the United States; excludes MOEs and transactions with targets industries of Energy, Insurance, Mining, Oil & Gas, REITs, Railroads, and Utilities

Appendix 12

CAPM approach – Bloomberg 5Y Weekly Beta at Optimal Capital Structure Cost of Equity Floor at Yield on Convertible Preferred Equity At Current Capital Structure Illustrative WACC Analysis – CAPM vs. Yield of Preferred Equity Source: Company filings, Bloomberg, Kroll, Mizuho, FactSet and Capital IQ as of 11/18/2022 Notes: (1) 5-year weekly Bloomberg Beta; Optimus Prime beta as of unaffected date (10/26/2022); all peer betas as of 11/18/2022 (2) Deloitte Corporate Tax Rates 2022 (3) Includes principal value of Term Loan B ($260.438M) and Optimus Prime Fruit Protection Loan ($0.897M) (4) Equity calculated as of 10/26/2022 using basic shares outstanding plus the effects of dilutive securities as of 11/18/2022; includes value of convertible preferred equity, reflecting change of control for Paine Schwartz Partners' convertible preferred equity at 2.0x MOIC assuming redemption date of 01/31/2023 (5) Kroll’s supply-side long term equity risk premium (6) 20-year treasury rate as of 10/26/2022 (7) Size premium interpolated based on Kroll size premia by market cap range using assumed optimal capital structure for Optimus Prime of 80% Equity / Capitalization (8) Based on effective yield for high-yield chemicals sector index (9) Refers to yield on Paine Schwartz Partners' preferred equity investment in Optimus Prime, ranging from 16% total annual coupon yield on to ~27% IRR on investment assuming redemption on 07/27/2023 ($ in millions)

Legal Disclaimer This Presentation has been provided to you by Perella Weinberg Partners and its affiliates (collectively “Perella Weinberg Partners” or the “Firm”) and may not be used or relied upon for any purpose without the written consent of Perella Weinberg Partners. The information contained herein (the “Information”) is confidential. By accepting this Information, you agree that you and your directors, partners, officers, employees, attorney(s), agents and representatives agree to use it for informational purposes only and will not divulge any such Information to any other party. Reproduction of this Information, in whole or in part, is prohibited. These contents are proprietary and a product of Perella Weinberg Partners. The Information contained herein is not an offer to buy or sell or a solicitation of an offer to buy or sell any corporate advisory services or security or to participate in any corporate advisory services or trading strategy. Any decision regarding corporate advisory services or to invest in the investments described herein should be made after, as applicable, reviewing such definitive offering memorandum, conducting such investigations as you deem necessary and consulting the investor’s own investment, legal, accounting and tax advisors in order to make an independent determination of the suitability and consequences of an investment or service. The information used in preparing these materials may have been obtained from or through you or your representatives or from public sources. Perella Weinberg Partners assumes no responsibility for independent verification of such information and has relied on such information being complete and accurate in all material respects. To the extent such information includes estimates and/or forecasts of future financial performance (including estimates of potential cost savings and synergies) prepared by or reviewed or discussed with the managements of your company and/or other potential transaction participants or obtained from public sources, we have assumed that such estimates and forecasts have been reasonably prepared on bases reflecting the best currently available estimates and judgments of such managements (or, with respect to estimates and forecasts obtained from public sources, represent reasonable estimates). The Firm has no obligation (express or implied) to update any or all of the Information or to advise you of any changes; nor do we make any express or implied warranties or representations as to the completeness or accuracy or accept responsibility for errors. Nothing contained herein should be construed as tax, accounting or legal advice. You (and each of your employees, representatives or other agents) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions contemplated by these materials and all materials of any kind (including opinions or other tax analyses) that are provided to you relating to such tax treatment and structure. For this purpose, the tax treatment of a transaction is the purported or claimed U.S. federal income tax treatment of the transaction and the tax structure of a transaction is any fact that may be relevant to understanding the purported or claimed U.S. federal income tax treatment of the transaction.